List of Excipients in Branded Drug XEPI

Last updated: September 2, 2026

ecutive summary: Xepi is a topical 1% ozenoxacin cream approved for impetigo in patients aged 2 months and older. Its commercial differentiation comes from a nonfluorinated quinolone antibiotic, low systemic exposure, twice-daily dosing for five days, and a relatively simple excipient system. The strongest development opportunities are generic or authorized-generic cream products, preservative-optimized formulations, pediatric and sensitive-skin variants, and regional products using equivalent excipient systems. Biosimilar competition is irrelevant because Xepi is a small-molecule drug. The principal commercial risk is rapid generic entry after loss of regulatory exclusivity, subject to current patent and Orange Book status.

Xepi Ozenoxacin Excipient Strategy, Patent Position, and Commercial Opportunities

What is Xepi and how is it used?

Xepi is a prescription topical cream containing ozenoxacin 1%, equivalent to 10 mg of active ingredient per gram of cream. The U.S. Food and Drug Administration approved Xepi in August 2017 for the topical treatment of impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes in patients aged 2 months and older.[1]

Attribute	Xepi profile
Brand name	Xepi
Active ingredient	Ozenoxacin
Strength	1% cream
Dosage form	Topical cream
FDA indication	Impetigo
Patient population	Adults and pediatric patients aged 2 months and older
Dosing	Apply a thin layer twice daily for five days
Original U.S. approval	2017
Regulatory pathway	NDA 208816
Therapeutic class	Topical quinolone antibacterial
Biosimilar exposure	None
Primary competitive threat	Generic ozenoxacin cream and alternative topical antibacterials

Xepi is applied to affected skin as a thin layer. The labeled course is short, which reduces total drug use and limits the value of large tube sizes. Commercial success therefore depends more on access, prescribing preference, pharmacy coverage, and unit price than on high-volume chronic use.

What excipients are used in Xepi cream?

The Xepi label identifies the following inactive ingredients:

Excipient	Functional role
Benzoic acid	Preservative and pH-modifying agent
Propylene glycol	Solvent, humectant, and penetration-supporting vehicle
Stearyl alcohol	Consistency agent and emulsion stabilizer
Polysorbate 20	Nonionic surfactant and emulsifier
Purified water	Aqueous phase

The formulation is an oil-in-water cream designed for spreadability and patient acceptability. It does not rely on a highly complex delivery platform, liposome, polymeric nanoparticle, or transdermal system. That simplicity lowers manufacturing barriers but also increases the likelihood that a generic manufacturer can develop a pharmaceutically equivalent product.

What is the commercial role of each Xepi excipient?

Benzoic acid is strategically important because it supports microbial control while also influencing formulation pH. Its presence can create tolerability considerations in very young patients or on compromised skin, although the approved product is labeled for use in infants aged 2 months and older.

Propylene glycol improves wetting and solubilization. It can also affect skin penetration and drying characteristics. Its concentration is commercially relevant because excessive levels may increase stinging or irritation, while insufficient levels may reduce active-ingredient uniformity.

Stearyl alcohol provides body and improves the cream’s sensory profile. It can help create a stable, semisolid product with acceptable rub-in properties. The excipient is distinct from ethanol and is not primarily included as an antimicrobial solvent.

Polysorbate 20 supports emulsion stability and helps distribute the active ingredient through the cream matrix. Changes in surfactant grade, concentration, or manufacturing order can affect viscosity, droplet size, assay uniformity, and long-term stability.

What formulation strategy should a generic Xepi developer use?

A generic developer should prioritize Q1/Q2 or Q3 similarity to the reference cream, depending on the applicable FDA product-specific guidance and review expectations. The development target is not only the same active ingredient and strength. The product should reproduce the reference formulation’s critical quality attributes.

Recommended development targets

Critical attribute	Commercial relevance
Ozenoxacin assay	Confirms labeled strength
Content uniformity	Important for semisolid dose consistency
Particle size and active distribution	Affects release and local delivery
pH	Influences stability, preservative performance, and tolerability
Viscosity	Determines spreadability and patient use
Globule or droplet size	Supports emulsion consistency
In vitro release rate	May support equivalence assessment
Microbial limits	Critical for a multidose topical product
Preservative effectiveness	Important because the product is aqueous
Stability under heat and freeze-thaw conditions	Supports global distribution

The first commercial opportunity is a conventional generic cream with matching strength, route, dosage form, and labeling. A lower-cost product that uses an equivalent excipient system could compete effectively if it achieves comparable appearance, stability, release, and application characteristics.

Which excipient modifications could create differentiation?

A developer could pursue several differentiated versions:

1. A lower-irritation formulation with reduced propylene glycol exposure.
2. A preservative-optimized formulation for sensitive or pediatric skin.
3. A fragrance-free and allergen-screened product for dermatology practices.
4. A cosmetically improved cream with faster rub-in and lower residue.
5. A larger or multi-pack presentation for institutional, school, or household use.
6. A regional formulation using locally available excipients while maintaining equivalent performance.
7. A formulation with improved cold-chain robustness for emerging markets.

These changes may create technical or regulatory value, but they can also trigger new comparability, stability, safety, or regulatory requirements. A new excipient system is commercially useful only if it improves a measurable attribute such as tolerability, adherence, manufacturing yield, or shelf life.

When does Xepi lose exclusivity?

Xepi’s five-year new chemical entity exclusivity would have expired in approximately August 2022, assuming the FDA granted standard NCE exclusivity beginning on the original approval date. The product is therefore exposed to generic development unless an enforceable patent, pediatric exclusivity period, regulatory stay, or other barrier delays approval.

Event	Date or timing
FDA approval	August 2017
Estimated end of five-year NCE exclusivity	August 2022
Current strategic issue	Patent listing and litigation status
Main post-exclusivity pathway	ANDA with Paragraph IV or Paragraph III certification

A pediatric population on the original label does not automatically establish six-month pediatric exclusivity. Pediatric exclusivity depends on completion of an FDA-issued written request and satisfaction of the statutory conditions.

What patents protect Xepi and its formulation?

The relevant intellectual-property categories are:

• Ozenoxacin compound patents.
• Salt, polymorph, or crystalline-form patents, if applicable.
• Topical composition patents.
• Cream stability or preservative-system patents.
• Methods of treating impetigo with ozenoxacin.
• Manufacturing-process patents.
• Use patents covering pediatric or resistant bacterial infections.

The Orange Book is the controlling public source for patents listed against the approved U.S. product. Patent scope and expiry should be assessed from the current Orange Book entry for NDA 208816, the underlying patent files, terminal disclaimers, maintenance-fee records, and any litigation docket. The FDA approval label alone does not establish the full patent estate.[2]

For an ANDA developer, the practical distinction is between patents that block approval and patents that create only litigation exposure. A listed method-of-use patent may be addressed through a section viii carve-out if the generic label can omit the patented indication. A composition-of-matter patent or broad formulation patent generally creates a more substantial barrier.

What patent claims are most valuable for Xepi?

The strongest potential claims would cover:

• The ozenoxacin molecule itself.
• A specific cream composition that is difficult to reproduce without infringement.
• A narrow particle-size or solubility profile required for performance.
• A manufacturing step that produces a necessary physical form.
• A formulation linked to a clinically meaningful improvement.

Broad claims covering routine cream ingredients are usually more vulnerable to invalidity or design-around arguments. Claims directed to a particular combination of ozenoxacin with a defined solvent, surfactant, pH range, viscosity range, or release profile may be more commercially relevant if supported by unexpected technical results.

What is the Orange Book status of Xepi?

Xepi is approved under NDA 208816. Orange Book analysis should focus on:

1. Whether patents are currently listed against NDA 208816.
2. Whether listed patents have expired.
3. Whether any patent has pediatric exclusivity attached.
4. Whether an ANDA applicant has filed a Paragraph IV certification.
5. Whether a timely infringement action triggered a 30-month stay.
6. Whether the NDA holder has entered a settlement with an ANDA applicant.

The existence of an Orange Book listing does not guarantee enforceability. Conversely, the absence of a listed patent does not eliminate non-Orange Book patent risk, including process or manufacturing claims.

Which companies are challenging Xepi?

Publicly verified challenger information must be evaluated through FDA ANDA records, Paragraph IV notice letters, federal court dockets, and settlement filings. Generic applicants may challenge Xepi through:

• Paragraph III certification, accepting delayed entry until patent expiry.
• Paragraph IV certification, asserting that patents are invalid, unenforceable, or not infringed.
• Section viii carve-out, where only a method-of-use claim is relevant.
• A 505(b)(2) application for a modified formulation or new indication.

No biosimilar pathway applies. Ozenoxacin is a chemically synthesized small molecule, and the principal regulatory route for a copy product is an ANDA rather than a biosimilar application.

What generic launch scenarios exist for Xepi?

Scenario	Commercial effect
First generic enters after patent expiry	Rapid price erosion and pharmacy substitution
Paragraph IV challenger launches at risk	Early price pressure and possible damages exposure
Multiple ANDAs enter together	Faster discounting and lower market share for the brand
Authorized generic launches	Brand owner preserves channel access while competing on price
Limited competition	Higher prices can persist if manufacturing economics are unattractive
505(b)(2) formulation enters	Differentiated product may avoid direct cream substitution

A conventional generic is likely to be the most economical challenge. The short treatment duration, simple formulation, and established topical route reduce development complexity relative to sterile, extended-release, or biologic products.

What commercial opportunities exist beyond the U.S.?

Ozenoxacin has potential in markets where impetigo, community-acquired bacterial skin infections, and antibiotic stewardship are commercial priorities. Regional opportunities include:

• Licensing local rights to dermatology-focused companies.
• Developing country-specific tube sizes and packaging.
• Using locally sourced excipients to lower cost.
• Producing aluminum tubes or laminate tubes matched to climate conditions.
• Establishing hospital and pediatric channels.
• Pairing the product with wound-care or dermatology portfolios.

Geographic patent coverage must be reviewed separately. U.S. expiry does not determine European, Latin American, Asian, or Middle Eastern freedom to operate. Product registration may also require local bridging data, stability studies, or excipient acceptability assessments.

What manufacturing barriers affect competition?

Manufacturing barriers are moderate rather than extreme. The critical risks are:

• Maintaining uniform ozenoxacin distribution in a semisolid matrix.
• Controlling temperature during emulsification.
• Preventing phase separation.
• Achieving reproducible viscosity.
• Managing preservative effectiveness.
• Maintaining microbial control during filling.
• Demonstrating container-closure compatibility.
• Reproducing in vitro release performance.

Tube selection is commercially relevant. A tube that adsorbs ozenoxacin, permits water loss, or changes cream viscosity can create stability and equivalence problems. Laminate and aluminum tubes may offer different protection against oxygen, moisture, and light.

How strong is the Xepi patent estate?

The commercial strength of the estate depends less on the existence of a compound patent than on the remaining term and the presence of enforceable formulation claims. Once NCE exclusivity ends, a generic applicant can proceed if no unexpired patent presents a valid barrier.

A strong estate would require at least one of the following:

• A long-lived composition-of-matter patent.
• A formulation patent covering the reference cream’s essential attributes.
• A patent that is difficult to design around while preserving equivalence.
• Enforceable method-of-use claims covering the only commercially important indication.
• A manufacturing claim tied to a required active form.

A simple ozenoxacin cream with common excipients is generally more exposed to generic substitution than a product based on a specialized delivery system.

How does Xepi compare with competing topical antibacterials?

Product	Active ingredient	Dosage form	Typical competitive position
Xepi	Ozenoxacin	1% cream	Nonfluorinated quinolone; five-day course
Bactroban	Mupirocin	Ointment or cream	Established impetigo treatment; broad generic competition
Altabax	Retapamulin	Ointment	Alternative topical antibacterial; limited differentiation
Generic mupirocin	Mupirocin	Ointment or cream	Low-cost formulary option
Oral antibiotics	Various	Tablets or liquids	Used when infection is extensive or topical therapy is unsuitable

Xepi’s strongest clinical-commercial differentiators are its quinolone mechanism, nonfluorinated structure, topical use, and short twice-daily regimen. Its weakness is that impetigo is commonly treated with inexpensive generic mupirocin, creating payer and formulary pressure.

Key Takeaways

• Xepi is a 1% ozenoxacin cream approved for impetigo in patients aged 2 months and older.
• Its excipient system contains benzoic acid, propylene glycol, stearyl alcohol, polysorbate 20, and purified water.
• The formulation is relatively simple and is therefore suitable for conventional generic development.
• Standard five-year NCE exclusivity likely ended in August 2022.
• Generic risk depends on the current Orange Book patent listings, patent expiry dates, Paragraph IV activity, and litigation settlements.
• Biosimilar competition does not apply.
• The most credible commercial opportunities are generic cream, authorized generic, pediatric-tolerability variants, preservative-optimized products, regional licensing, and packaging improvements.
• Formulation patents are strongest when they cover measurable performance attributes that are difficult to design around.

FAQs About Xepi Excipient and Commercial Strategy

Can propylene glycol be removed from a generic Xepi formulation?

Removal is technically possible but may change ozenoxacin solubility, release, spreadability, preservative performance, and skin tolerability. A reformulated product would require a regulatory strategy distinct from a direct generic approach.

Is Xepi suitable for a 505(b)(2) product?

A 505(b)(2) strategy could be relevant for a new delivery system, extended-contact formulation, different dosage form, or new indication. A conventional equivalent cream would generally be better suited to the ANDA pathway.

Could a preservative-free Xepi cream be commercialized?

A preservative-free multidose cream would face significant microbial-control and packaging requirements. Unit-dose packaging could address contamination risk but would increase packaging cost and may weaken the product’s price advantage.

Does Xepi have a biosimilar market?

No. Ozenoxacin is a small-molecule active ingredient. Competitive copies would ordinarily use the generic-drug framework, not the biologics biosimilar pathway.

Is a pediatric Xepi formulation commercially attractive?

Potentially. The approved age range already includes infants aged 2 months and older, so the opportunity is more likely to involve improved tolerability, packaging, dosing usability, or patient acceptance than a new pediatric indication.

References

1. U.S. Food and Drug Administration. (2017). Xepi (ozenoxacin) cream, 1%: Prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. National Library of Medicine. (2025). DailyMed: Xepi (ozenoxacin) cream.
4. U.S. Food and Drug Administration. (2024). Generic drug user fee amendments and abbreviated new drug application resources.